OncoGenex Pharmaceuticals

OncoGenex’s phase II Rainier study shows poor results

Thursday, September 24, 2015

OncoGenex Pharmaceuticals has reported initial results from the phase II Rainier study evaluating apatorsen in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to Abraxane and gemcitabine alone in patients with untreated metastatic pancreatic cancer. The addition of apatorsen to Abraxane and gemcitabine did not demonstrate a survival benefit compared to Abraxane and gemcitabine alone. The study was sponsored and conducted by Sarah Cannon Research Institute (SCRI).

[Read More]

OncoGenex regains rights to custirsen from Teva

Wednesday, April 29, 2015

OncoGenex Pharmaceuticals has announced its wholly owned subsidiary, OncoGenex Technologies, executed a termination agreement with Teva under which OncoGenex will regain rights to custirsen, an investigational compound currently in phase III clinical development as a treatment for prostate and lung cancers. This transfer of rights occurs in connection with the termination of the 2009 collaboration agreement between OncoGenex and Teva.

[Read More]

OncoGenex to initiate phase II trial of OGX-427 in non-squamous NSCLC

Friday, April 12, 2013

OncoGenex Pharmaceuticals, a biopharmaceutical company, plans to initiate an investigator-sponsored, randomized, double-blind, placebo-controlled phase II study, Spruce, evaluating OGX-427 in patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC). The trial will investigate whether adding OGX-427 to carboplatin and pemetrexed therapy can extend progression-free survival (PFS) outcomes.

[Read More]